调肝运脾方治疗腹泻型肠易激综合征临床研究

叶柏; 陈静; 宁丽琴; 刘春; 曹婷婷

调肝运脾方治疗腹泻型肠易激综合征临床研究

南京中医药大学附属医院，江苏南京 210029

计量
- 文章访问数: 615
- HTML全文浏览量: 4
- PDF下载量: 651
- 被引次数: 0
出版历程
- 收稿日期: 2013-03-10
- 修回日期: 2013-04-28
- 刊出日期: 2013-07-10

Clinical Study of Regulating Liver and Activating Spleen Therapy for Diarrhea-Irritable Bowel Syndrome

摘要

摘要: 目的评价调肝运脾方治疗腹泻型肠易激综合征(D-IBS)肝郁脾虚证的临床疗效和安全性。方法 96例符合纳入标准的D-IBS患者随机分为治疗组48例和对照组48例，其中治疗组1例和对照组2例在首次就诊后均未来院复诊而脱落。治疗组服用中药调肝运脾方，对照组服用得舒特治疗，2组服药时间均为4周。观察并记录治疗前后D-IBS症状、体征积分变化以及治疗前后的相关检验指标变化。结果在总有效率及愈显率方面，治疗组优于对照组（P＜0.05）。2组治疗后症状总积分较治疗前均显著下降（P＜0.01），治疗组明显优于对照组，P＜0.01。治疗组治疗后各主要症状积分均比治疗前显著下降（P＜0.05）；对照组除排便不尽感外，各主要症状积分较治疗前也有所改善（P＜0.05），但治疗组在腹痛或腹部不适、大便次数、大便性状等症状积分改善方面明显优于对照组（P＜0.05）。治疗组及对照组治疗后均未出现任何不良反应，2组患者治疗前后分别检测血常规、尿常规、粪常规、丙氨酸氨基转移酶（ALT）、血尿素氮(BUN)、血清肌酐(Scr)，均未发现异常。结论调肝运脾方治疗D-IBS临床疗效显著，具有良好安全性。
- 调肝运脾方 /
- 肠易激综合征 /
- 临床研究
Abstract: OBJECTIVE To assess the effect of regulating liver and activating spleen therapy on patients with diarrhea-irritable bowel syndrome (D-IBS) belonging to liver depression and spleen deficiency type as well as its safety.METHODS 96 cases conforming to the including criteria were randomly divided into treatment group and control group with 48 in each. 1 case of the treatments and 2 cases of the controls fell off as they did not return visit since the first consultation. The treatment group were given traditional Chinese medical formula Tiaogan Yunpi Fang for regulating liver and activating spleen， the control group were administrated with Deshute. The course of two groups was 4 weeks. Symptoms， signs and tests results of the patients before and after treatment were collected and analyzed. RESULTS The treated patients were better than control patients in total effective rate and recovery rate (P<0.05). Symptom score of both groups significantly decreased after treatment， but the treatment group was superior to the control (P<0.01). The symptom score of treatment group decreased in comparison with that before treatment (P<0.05). All the symptoms of control patients were improved except for non-complete defecation (P<0.05). However， abdominal pain and discomfort， defection frequency， feces property of the treated patients were improved significantly， much better than those of the control (P<0.05). There was no adverse reaction in two groups. Regular blood test， urine test， stool test， ALT， BUN， Scr were not found abnormal. CONCLUSION Tiaogan Yunpi Fang is effective on D-IBS with great safety.
- regulating liver and activating spleen therapy /
- irritable bowel syndrome /
- clinical study

HTML全文

参考文献(14)

[1]	中华医学会消化病分会.胃肠动力学组[J].中华消化杂志，2008，28(1)：38-40.
[2]	Digestive Diseases Branch of Chinese Medical Association. GI dynamics group[J]. Chin J Dig， 2008，28(1):38-40.
[3]	中药新药临床研究指导原则(试行) [M].北京：中国医药科技出版社，2002：162-165.
[4]	Chinese medicine clinical research guidelines(trial)[M]. Beijing: China medical science press， 2002:162-165.
[5]	吴昆.医方考[M].北京：人民卫生出版社，2007:136.
[6]	Wu K. Textual Research on Medical Formulas[M]. Beijing:People's medical publishing house， 2007:136.
[7]	王泰林.王旭高医书六种[M].上海：上海科学技术出版社，1965:86.
[8]	Wang TL. Six medical books of Wang Xugao[M]. Shanghai: Shanghai scientific and technical publishers， 1965:86.
[9]	林琳，张红杰，赵志泉，等．胃肠肽类激素与肠易激综合征发病间的关系[J]．南京医科大学学报，2003，23（6）：527-530.
[10]	Lin L， Zhang HJ， Zhao ZQ， et al. Relationship between irritable bowel syndrome and gastrointestinal hormones[J]. J Nanjing Med Univ， 2003，23(6):527-530.
[11]	叶天士.临症指南医案[M].上海：上海科学技术出版社，1997:385.
[12]	Ye TS. Case records as a guide to clinical practice[M]. Shanghai: Shanghai scientific and technical publishers， 1997:385.
[13]	张介宾.景岳全书[M].北京：人民卫生出版社，1997:519.
[14]	Zhang JB. The complete works of Zhang Jing-yu[M]. Beijing: People's medical publishing house， 1997:519.